Comparison Between Iliopsoas Block (IPB) and Pericapsular Nerve Group (PENG) Block on Postoperative Analgesia and Functional Recovery After Total Hip Arthroplasty Surgery: a Double-blinded Randomized Clinical Trial

Background:
In recent years, regional anesthesia has become more popular because it can reduce pain and the need for strong pain medications like morphine. For hip surgery, the PENG block is already known to be effective. A newer method, called the iliopsoas plane block (IPB), is very similar and has also shown good results in hip arthroscopy. However, these two techniques have never been directly compared in patients undergoing hip replacement surgery using the posterior approach.
Goal:
This study aims to see if the IPB is just as effective as the PENG block for controlling pain and helping patients recover well after hip replacement surgery.
Method:
118 adult patients scheduled for hip replacement under spinal anesthesia will be randomly assigned to receive either: IPB: 7 ml of Ropivacaine 7.5 mg/ml PENG: 14 ml of Ropivacaine 3.75 mg/ml Both injections are given under ultrasound guidance 30 minutes before spinal anesthesia. Neither the patient, the surgeon, nor the data collector will know which technique was used.
Post-Surgery Care:
All patients will receive standard pain relief, including:
Paracetamol every 6 hours Etoricoxib once a day Morphine via a patient-controlled pump for 48 hours
Main Outcome Measured:
The primary goal is to compare pain during movement 6 hours after surgery, using a pain scale from 0 (no pain) to 10 (worst pain). The study will consider the two blocks equivalent if the difference in average pain scores is less than 1 point.
Other Outcomes:
Total morphine used in 48 hours Pain scores at rest and during movement at various time points Walking ability (2- and 6-minute walk tests, and timed-up-and-go test) Quality of recovery (using the QoR-15 questionnaire) Side effects of morphine Patient satisfaction Length of hospital stay
Safety:
Both techniques are safe and already used in clinical practice. Ultrasound guidance minimizes risks like nerve injury, bleeding, or infection.
Conclusion:
If the IPB is shown to be as effective as the PENG block, both can be considered reliable options for pain control and early recovery after hip replacement surgery.

开始日期2025-10-01

申办/合作机构

University of Liege

[+1]

NCT07031518

/ RecruitingN/AIIT

Pilot Study to Identify and Validate Digital Biomarkers in Osteoarthritis of the Knee

To date, treatment options for knee osteoarthritis remain limited, and their clinical evaluation is complex due to the day-to-day fluctuations in symptoms.
Hospital tests provide a point-in-time measurement that is influenced by various factors (fatigue, recent activity, weather, etc.), making reliable assessment difficult. The aim of the study is to assess the feasibility and acceptability of monitoring actual activity using the Syde® portable device in up to 30 subjects. Numerical variables derived from data collected by Syde® will be compared with conventional on-site clinical assessment criteria and with data from healthy participants, in order to identify a reliable and robust metric, thereby improving treatment evaluation and personalised patient management.
MAIN OBJECTIVES
* Evaluate the use of the device
* Identify numerical variables and determine the optimal time window for evaluation
Patients will have two visits: one at inclusion and a second two months later. They will wear Syde® magneto-inertial sensors, one on each ankle, for the month following the initial visit, then a Syde® sensor on the ankle and another on the wrist on the side of the non-dominant hand for the following month. The total duration of the recording period is two months.

开始日期2025-05-14

申办/合作机构

Centre Hospitalier Universitaire de Liege

[+2]

NCT06916871

/ Not yet recruitingN/AIIT

Optimizing Care for Diabetic Patients in Hospitalized Rehabilitation Through Structured Education.

A large number of patients at the Neurological and Functional Rehabilitation Centre of the University Hospital of Liège have associated pathologies, including diabetes. These patients may have diabetes-related complications that require recurrent hospitalizations in an acute structure or in rehabilitation. One of the ways to limit complications is to set up patient education.
1. Objectives
* To compare the impact of management through formal education with that of awareness.
* To evaluate the impact on knowledge of structured education.
* To evaluate the impact of structured education on the quality of life experienced by diabetic patients.
* Identify the patient's level of satisfaction with the education sessions.
* To evaluate the impact of structured education on the biological improvement of glycated hemoglobin.
* To evaluate the impact of structured education on diabetes-related complications.
2. Working Hypothesis The implementation of structured diabetes education allows "patients to acquire, or maintain, the skills they need to manage their lives as well as possible despite the constraints of chronic disease... ".
3. Study population All diabetic patients hospitalized in all care units.
4. Collection tools and techniques Collection tools
1. "Diabetes Knowledge Questionnaire". 2. SF-36 Health Questionnaire. 3. Satisfaction questionnaire for structured sessions on diabetes. 4. Questionnaire to identify complications and/or re-hospitalizations after your stay in rehabilitation.
Collection technology At admission (D+1)
* Validation of inclusion and exclusion criteria.
* Submission and distribution of the information and consent form.
* Obtaining informed consent from the patient.
* Distribution of collection tools 1 and 2 (collection on D+2).
* Control of glycated hemoglobin. At the end of hospitalization (D-2)
* Distribution of collection tools 1, 2 and 3 on D-2 before the release (collection on D-1).
* Control of glycated hemoglobin. 3 months after the end of hospitalization
* Sending collection tools 1, 2 and 4 by post. The patient will be invited to complete them and return them by post.
* The patient will be invited to take a blood test for glycated hemoglobin.

开始日期2025-04-07

申办/合作机构

Centre Hospitalier Universitaire de Liege

100 项与 Centre Hospitalier Universitaire de Liege 相关的临床结果

登录后查看更多信息

0 项与 Centre Hospitalier Universitaire de Liege 相关的专利（医药）

登录后查看更多信息

825

项与 Centre Hospitalier Universitaire de Liege 相关的文献（医药）

2025-06-03·Expert Review of Anticancer Therapy

Current treatment options for locally advanced and metastatic basal cell carcinoma. A narrative review

Review

作者: Piret, Pascal ; Rorive, Andrée ; Nikkels, Arjen F. ; Marchal, Nathalie ; Absil, Gilles

INTRODUCTION:

Although basal cell carcinomas (BCC) are the most common skin cancer and usually considered as 'easy-to-treat,' locally advanced BCC (laBCC) and metastatic BCC (mBCC) are rather exceptional and often more 'difficult-to-treat.' They load a high burden on the quality of life (QoL) of the patients, often elderly and frail individuals. Several management options are possible, varying from supportive therapy without any therapeutic intervention until anti-programmed cell death protein-1 (PD-1) immunotherapy, such as cemiplimab, either administered intravenously or intralesional. In between this spectrum, oral hedgehog inhibitors including vismodegib and sonidegib, electrochemotherapy, different types of radiotherapy, and surgery can be considered. CAR-T cell therapy, anti-LAG therapy, and multiple combination therapies are currently under investigation for laBCC and mBCC.

AREAS COVERED:

Current and future treatment options for the management of laBCC and mBCC, limitations of different approaches as well as some practical and financial aspects are presented.

EXPERT OPINION:

The management of laBCC and mBCC patients is determined by a multidisciplinary dermato-oncology board, including dermatologists, medical oncologists, radiotherapists, pathologists, and surgeons, as well as the patient's GP. Today, experts recommend keeping as long as possible laBCC and mBCC patients under sequential courses of HHIs, if surgery and/or radiotherapy are not amenable.

2025-06-01·ANESTHESIA AND ANALGESIA

The Old Drug Ketamine Keeps on Surprising Us

Article

作者: Bonhomme, Vincent L.

2025-06-01·Lancet Diabetes & Endocrinology

Experience evolves into evidence in the new MEN1 guidelines

Article

作者: Daly, Adrian F

项与 Centre Hospitalier Universitaire de Liege 相关的新闻（医药）

2025-03-10

·Firstwordpharma

J&J's oral IL-23 peptide icotrokinra delivers in UC after psoriasis triumph

Johnson & Johnson's icotrokinra (JNJ-2113) met the primary endpoint of a Phase IIb ulcerative colitis (UC) study, building on its recent success in psoriasis. The IL-23-blocking oral peptide could also boost the company's efforts to stay ahead in immunology as Stelara (ustekinumab) stares down biosimilar competition.In the ANTHEM-UC study, J&J tested three once-daily doses of icotrokinra and found that the highest one led to a clinical response in 63.5% of patients after 12 weeks, compared to just 27% for placebo. The drug also showed "meaningful differences" on secondary measures like clinical remission, with 30.2% of patients on the highest dose achieving remission versus 11.1% for placebo. J&J said the benefits kept improving through week 28, with a favourable safety profile.The trial enrolled 252 patients with moderately to severely active UC who'd had an inadequate response or intolerance to conventional therapy. More ANTHEM-UC results will be shared at upcoming medical congresses."These impressive findings show the potential of icotrokinra to transform the treatment paradigm… by offering a distinctive combination of therapeutic benefit, tolerability, and convenience with a once-daily oral treatment," said Esi Lamousé-Smith, gastroenterology disease area lead at J&J, in a release Monday.The icotrokinra results complement J&J's recent efforts to strengthen its IL-23 lineup, including September's FDA approval of Tremfya (guselkumab) for UC with intravenous induction and subcutaneous maintenance, and a pending application for a fully subcutaneous regimen. According to data presented last month, Tremfya's SC induction demonstrated significantly higher rates of clinical remission (27.6% vs 6.5%) and response (65.6% vs 34.5%) versus placebo at week 12 in the Phase III ASTRO trial.Both icotrokinra and Tremfya are being positioned to help offset expected revenue declines from Stelara, which saw a 4.6% global sales drop in 2024 as biosimilars enter the market.The UC data for icotrokinra follows its strong showing in psoriasis at the American Academy of Dermatology (AAD) meeting over the weekend. The ICONIC-ADVANCE 1 and 2 trials not only met their primary endpoints of achieving clear or nearly clear skin, but also demonstrated superiority to Bristol Myers Squibb's oral TYK2 inhibitor Sotyktu (deucravacitinib). See – ViewPoints: AAD25 – J&J leadership tells how icotrokinra is upping the ante across the board in psoriasis.

临床结果临床3期上市批准临床2期

2025-02-11

·今日头条

刚刚！强生两款抗癌新药在中国获批！重锤肺癌及多发性骨髓瘤

就在刚刚，抗癌圈传来两则激动人心的好消息！ 2025年2月11日，强生制药两款抗癌药——塔奎妥单抗、埃万妥单抗成功获得中国国家药品监督管理局（NMPA）的上市批准。其中，塔奎妥单抗获批用于治疗成人复发或难治性多发性骨髓瘤；而埃万妥单抗（强生旗下的杨森制药）注射液则被批准用于EGFR 20ins突变的局部晚期或转移性非小细胞肺癌的一线治疗。这两款药物的获批，将为相关癌症患者带来新的治疗选择和希望！ ▲截图源自“NMPA” 一、塔奎妥单抗在华重磅获批，超60%复发性或难治性骨髓瘤患者迎来转机塔奎妥单抗（Talquetamab）是一种First-in-Class双特异性抗体和人源化单克隆抗体，同时也是一种CD3E调节剂，本次在我国获批用于成人复发或难治性多发性骨髓瘤的治疗。早在2023年8月9日，该药就已获得美国食品药品监督管理局（FDA）的加速批准，用于成人既往已接受过至少4种治疗（包括免疫调节剂、CD38单克隆抗体、蛋白酶体抑制剂抗）的复发性或难治性多发性骨髓瘤的治疗。塔奎妥单抗在海外顺利获批，主要基于一项MonumenTAL-1（NCT03399799）临床研究的惊艳数据。本次共纳入232例多发性骨髓瘤患者，入组接受了塔奎妥单抗治疗，中位随访时间为11.7个月（接受405μg剂量水平）、4.2个月（接受800μg剂量水平），有反应的患者百分比分别为70%（95%CI，51~85）、64%（95%CI，48~78）（详见下图）。 ▲图源“N Engl J Med”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除大多数患者的缓解随时间推移而加深（即从部分缓解改善为非常好的部分缓解或更佳）。中位缓解持续时间分别为10.2个月（接受405 μg 剂量塔奎妥单抗治疗的患者，95% CI，3.0 ~未达到）， 7.8个月（接受800 μg 剂量塔奎妥单抗治疗的患者，95% CI，4.6~未达到）（详见下图）。 ▲图源“N Engl J Med”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除二、埃万妥单抗：全球首款EGFR/cMET双抗在我国获批，73%客观缓解率完胜非小细胞肺癌单纯化疗埃万妥单抗（Amivantamab，Rybrevant，代号JNJ6372）是由强生旗下的杨森制药研发的一款EGFR间充质-上皮转化因子（c-Met/EGFR）双特异性抗体，具有免疫细胞导向活性，可以%绕过EGFR外显子 20 插入的 NSCLC 患者对酪氨酸激酶抑制剂的配体位点耐药性，将 MET 作为旁路耐药机制，并募集效应细胞发挥抗癌作用。本次在我国获批，用于EGFR 20ins突变的局部晚期或转移性非小细胞肺癌的一线治疗！此前该药的静脉注射剂型已在欧美、日本等国获批上市，埃万妥单抗也成为了全球首个获批的c-Met/EGFR双抗类药物！埃万妥单抗在海外顺利获批，主要基于一项3 期国际随机 PAPILLON临床试验（NCT04538664）的惊艳数据！本次共入组308例≥18岁、EGFR 20ins插入突变的局部晚期或转移性非小细胞肺癌（NSCLC ）患者，将其随机分为两组，即埃万妥单抗（Amivantamab）组（n=153例，接受埃万妥单抗+化疗）、单独化疗组（n=155例，仅接受化疗）。中位随访时间为14.9个月，结果显示如下： 1、中位无进展生存期（PFS）：埃万妥单抗（Amivantamab）联合化疗组的无进展生存期（PFS）显著长于化疗组，中位PFS分别为 11.4个月（埃万妥单抗联合化疗组） vs 6.7个月（单独化疗组）（详见下图）。 ▲图源“N Engl J Med”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 2、客观缓解率（ORR）：客观缓解率（ORR，完全或部分缓解）分别为 73%（埃万妥单抗联合化疗组，95% CI，65~80） vs 47%（单独化疗组，95% CI，39~56）（详见下图）。 ▲图源“N Engl J Med”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除综上，作为晚期EGFR外显子20插入非小细胞肺癌（NSCLC）患者的一线治疗，埃万妥单抗联合化疗的疗效优于单纯化疗。阅读原文了解近期有望获批的更多抗癌药：救命药要来了！2025十五款抗癌新药即将登陆中国，横扫肺癌、乳腺癌、鼻咽癌等八大癌种三、小编温馨提示想了解塔奎妥单抗、埃万妥单抗或抗癌新药更多讯息的患者，需将近期病理报告、基因检测报告等资料，提交至全球肿瘤医生网医学部，进行初步评估或疗效详细的入排标准。四、参考资料 [1]Chari A,et al.Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma[J]. New England Journal of Medicine, 2022, 387(24): 2232-2244. https://www-nejm-org.libproxy1.nus.edu.sg/doi/full/10.1056/NEJMoa2204591 [2]Zhou C,et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions[J]. New England Journal of Medicine, 2023, 389(22): 2039-2051. https://nejm-org.libproxy1.nus.edu.sg/doi/full/10.1056/NEJMoa2306441 本文为全球肿瘤医生网原创，未经授权严禁转载

临床结果上市批准加速审批

100 项与 Centre Hospitalier Universitaire de Liege 相关的药物交易

登录后查看更多信息

100 项与 Centre Hospitalier Universitaire de Liege 相关的转化医学

登录后查看更多信息